European Savings From Small-Molecule Generic Launches Likely To Tail Off
This article was originally published in The Pink Sheet Daily
Executive Summary
Encouraging use of generics is one of few policy measures over past decades to generate large savings for U.K.’s National Health Service, but time may be running out for European countries to make major savings from declining number of new small-molecule generics.
You may also be interested in...
Biosimilar Cost Savings In Europe Beyond 25% Might Cull Sponsors, EGA Warned
Trade association hears pricing discipline and differentiated products are keys to sustaining European biosimilars market even as it continues to grow.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.